 | | | | LONDON (Reuters) - AstraZeneca's immunotherapy drug Imfinzi has won crucial approval from U.S. regulators for use in lung cancer, opening up a multibillion-dollar market for a medicine that has so far lagged behind competitors. | | | | | | (Reuters Health) - The number of babies dying of suffocation before their first birthday has been rising in recent years, driven at least in part by an increase in the number of parents sharing beds with their infants, a U.S. study suggests. | | | | | | (Reuters Health) - Injuries to a critical ligament in the knee are becoming more common in children and teens, researchers warn. | | | | | | BLANTYRE (Reuters) - Cholera cases in Malawi have tripled and four more people have died, the Ministry of Health said on Monday, a month after the spread of the disease from Zambia was thought to have been contained. | | | | | | (Reuters) - A federal judge in Delaware has overturned a jury's verdict requiring Gilead Sciences Inc to pay a record $2.54 billion because its hepatitis C drugs Sovaldi and Harvoni infringed a patent held by rival Merck & Co Inc. | | | | | | (Reuters) - The U.S. Food and Drug Administration on Friday declined to approve Apricus Biosciences Inc's Vitaros, a cream to treat erectile dysfunction, for the second time in a decade, sending the company's shares down more than 70 percent before the opening bell. | | | | | | (Reuters Health) - Babies who are born much too soon or who arrive weighing too little may not score as high on intelligence tests during childhood as full-term infants, a research review suggests. | | | | | | (Reuters Health) - In the first year after being told by a doctor that they have acne, patients' risk for a diagnosis of major depressive disorder spikes by more than 60 percent compared to the general population, a new study shows. | | | | | | (Reuters) - Switzerland's Novartis AG is preparing to auction its U.S. generic pill business, looking to shed a unit that has struggled amid fierce price competition, people familiar with the matter said on Friday. | | | | | | (Reuters Health) - A shortage of clinicians specializing in pediatric behavioral and developmental disorders is translating into long wait times for new patient appointments amid surging demand, a new study suggests. | | | | | |
